QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions
Retrieved on:
Tuesday, October 19, 2021
Biotechnology, Medical Supplies, Health, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Other Health, Calibration, Molecular diagnostics, Union, Life, Richard Estick, List of life sciences, Technology, Commission on Sustainable Development, COVID-19, Budget, Lung, Diagnosis, QGEN, Stop TB Partnership, NYSE, Growth, Transport, Tuberculosis, RNA, Annual report, Disease, Lists of disasters, Weather, Knowledge, U.S. Securities and Exchange Commission, Infection, CEO, QIAGEN, Patient, CE, QuantiFERON, Automation, Clinical, Conference, TB, Protein, Partnership, Interferon gamma release assay, ZAMBART Project, Blood, Solution, IGRA, DNA, Marketing, Maintenance, Data management, Heating, ventilation, and air conditioning, Medical imaging, Pharmaceutical industry
QIAGEN will focus on regions that face a high burden of the disease, and where getting access to lab infrastructure and resources for testing are limited.
Key Points:
- QIAGEN will focus on regions that face a high burden of the disease, and where getting access to lab infrastructure and resources for testing are limited.
- With QIAreach QuantiFERON-TB we have taken a great step towards leaving no one behind when facing a deadly disease like tuberculosis that is preventable and curable.
- A quantum leap from the traditional TB skin test, QuantiFERON-TB uses blood samples to test for interferon-gamma molecules released from T-cells that have come into contact with TB bacteria.
- QIAreach QuantiFERON-TB runs these tests on the digital eHub and eStick system, a true walkaway solution with random access and no calibration or maintenance.